newsfilter
← Latest News
PR Newswire·

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

  • Viking Therapeutics announced that CEO Brian Lian, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference.
  • The conference is scheduled for January 12-15, 2026, in San Francisco, California.
  • Dr. Lian's presentation is set for 2:15 – 2:55 p.m. Pacific time on Monday, January 12, 2026.
  • A live webcast of the presentation will be available on the Viking Therapeutics website, with a replay accessible after the event.
  • Viking is advancing VK2735, a dual GLP-1 & GIP receptor agonist, through Phase 3 trials (VANQUISH-1 & VANQUISH-2) for obesity.
  • The company is also evaluating an oral formulation of VK2735 for obesity treatment.
  • VK2809, an oral selective thyroid hormone receptor beta agonist, successfully met endpoints in a Phase 2b study for NASH & fibrosis.
  • Phase 2a data for VK2809 showed significant reductions in LDL-C & liver fat for NAFLD & elevated LDL-C patients.
  • Viking is developing dual amylin & calcitonin receptor agonists (DACRAs) for obesity & metabolic disorders.
  • The company is testing VK0214, an oral thyroid hormone receptor beta agonist, for X-linked adrenoleukodystrophy (X-ALD).
  • Phase 1b results for VK0214 demonstrated safety & significant reductions in very long-chain fatty acids for the AMN form of X-ALD.